St. Jude Children's Research Hospital

FDA accepted Merck's BLA for clesrovimab to prevent RSV in infants, with a PDUFA date of June 10, 2025. Clesrovimab showed significant reductions in RSV-associated medically attended lower respiratory infections, hospitalizations, and severe MALRI in clinical trials.

The Cancer History Project, launched in 2021, aims to preserve oncology's history, exploring milestones like EGFR mutations in lung cancer and the 1964 Surgeon General's Report on Smoking and Health. The project, supported by The Cancer Letter, features multimedia series, podcasts, and institutional histories, attracting growing readership.

1000 children aged 0–14 in Australia/New Zealand are diagnosed with cancer annually, with paediatric brain cancers causing 40% of cancer-related deaths despite representing only 14% of diagnoses. Although overall cure rates exceed 80%, many brain tumour types have bleak outlooks, and survivors often face lifelong clinical sequelae. The Australian Brain Cancer Mission (ABCM) and the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) have addressed challenges in clinical trial execution, leading to the initiation or expansion of 11 clinical trials. These trials aim to improve survival rates and quality of life for children with aggressive brain cancers, leveraging international collaborations and innovative treatments. Despite progress, challenges remain in funding and resource constraints, necessitating sustained strategic funding and international partnerships to advance paediatric brain cancer research.

Philip John Dye, a lifelong Akron resident, passed away suddenly on November 12, 2024. He was a graduate of Buchtel High School and the University of Akron, a former Akron Police Department Sergeant, and a custom home builder. Dye later co-founded a medical supply company with his wife Susan, where he designed and patented the Z-Cath catheter. He was a devoted family man and community member, leaving behind his wife, children, grandchildren, and siblings. A private service will be held, with donations in his memory directed to St. Jude Children's Research Hospital.

Researchers made a breakthrough in treating advanced breast cancer, potentially doubling survival time. Eddy Alvarez rescues homeless dogs in South Florida. Lyft and Uber offer 50% off rides to polling locations on Election Day. Early voting options have expanded significantly in the last 24 years. Sarah McBride became the first openly transgender person elected to U.S. Congress. A cloned black-footed ferret gave birth for the first time. Voters in California, Colorado, and Hawaii passed measures to secure protections for same-sex marriage. The Texas woodpecker is no longer endangered. Bozeman, Montana voted to ban single-use plastic bags.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

Mitchell J. Weiss, MD, PhD, chair of St. Jude Children’s Research Hospital Department of Hematology, elected to National Academy of Medicine (NAM) for research in blood cell formation and treatment development for sickle cell disease and beta-thalassemia. Weiss has published over 170 research papers and joined six other St. Jude faculty members in NAM.

St. Jude Children's Research Hospital clinical trials show that genomics and early treatment response can guide risk classification in B-cell acute lymphoblastic leukemia (B-ALL), allowing for low-intensity chemotherapy in certain genetic subtypes (ETV6::RUNX1 and high-hyperdiploid) to achieve positive outcomes, as published in the journal *Blood*.

Billionaire Jared Isaacman, with SpaceX, aims for first private spacewalk, reaching 870 miles altitude, surpassing NASA's Gemini record. The five-day flight includes testing new spacesuits and a 10-hour stay at extreme height before descending. Isaacman and Sarah Gillis will conduct the spacewalk, monitored by Scott Poteet and Anna Menon from inside.